Emmessar Biotech Intrinsic Value
Emmessar Biotech intrinsic value. Emmessar Biotech (EMMESSA) median intrinsic value is ₹12.00 from 8 valuation models (range ₹7–₹19), vs current price ₹23.67 — -49.3% downside (Trading Above Calculated Value), margin of safety -97.3%. Compare with Emmessar Biotech value estimation to assess whether the stock is under or overvalued.
EMMESSA Valuation Methods Summary — DCF, Graham Number & P/E
Emmessar Biotech intrinsic value across 8 models vs current price ₹23.67 — upside/downside and value range per method. Read Emmessar Biotech dividend payments for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹8.40 | ₹6.72 - ₹10.08 | -64.5% | EPS: ₹0.70, Sector P/E: 12x |
| Book Value Method | asset | ₹16.00 | ₹14.40 - ₹17.60 | -32.4% | Book Value/Share: ₹16.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹7.10 | ₹6.39 - ₹7.81 | -70.0% | Revenue/Share: ₹4.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹12.00 | ₹10.80 - ₹13.20 | -49.3% | EBITDA: ₹1.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹18.57 | ₹14.86 - ₹22.28 | -21.5% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹7.10 | ₹6.39 - ₹7.81 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹7.10 | ₹6.39 - ₹7.81 | -70.0% | Revenue Growth: -9.6%, Adj P/E: 8.0x |
| Graham Defensive Method | conservative | ₹15.87 | ₹14.28 - ₹17.46 | -33.0% | EPS: ₹0.70, BVPS: ₹16.00 |
EMMESSA Intrinsic Value vs Market Price — All Valuation Models
Emmessar Biotech fair value range ₹7–₹19 vs current market price ₹23.67 across 8 valuation models. For current market price and key ratios, visit Emmessar Biotech stock price NSE.
EMMESSA Intrinsic Value Analysis — Undervalued or Overvalued?
Emmessar Biotech median intrinsic value ₹12.00, current price ₹23.67 — Trading Above Calculated Value by 49.3%, margin of safety -97.3%.
What is the intrinsic value of EMMESSA?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Emmessar Biotech (EMMESSA) is ₹12.00 (median value). With the current market price of ₹23.67, this represents a -49.3% variance from our estimated fair value.
The valuation range spans from ₹7.10 to ₹18.57, indicating ₹7.10 - ₹18.57.
Is EMMESSA undervalued or overvalued?
Based on our multi-method analysis, Emmessar Biotech (EMMESSA) appears to be trading above calculated value by approximately 49.3%.
EMMESSA Financial Health — Key Ratios vs Industry Benchmarks
Emmessar Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | -446.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.20x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
EMMESSA Cash Flow Quality — Operating & Free Cash Flow
Emmessar Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |